The DOI matches its Crossref record; the references it cites are not checked yet.
Replication Protein A Availability during DNA Replication Stress Is a Major Determinant of Cisplatin Resistance in Ovarian Cancer Cells
Published version of a preprint
Abstract
Intrinsic and acquired resistance to cisplatin remains a primary hurdle to treatment of high-grade serous ovarian cancer (HGSOC). Cisplatin selectively kills tumor cells by inducing DNA crosslinks that block replicative DNA polymerases. Single-stranded DNA (ssDNA) generated at resulting stalled replication forks (RF) is bound and protected by heterotrimeric replication protein A (RPA), which then serves as a platform for recruitment and activation of replication stress response factors. Cells deficient in this response are characterized by extensive ssDNA formation and excessive RPA recruitment that exhausts the available pool of RPA, which (i) inhibits RPA-dependent processes such as nucleotide excision repair (NER) and (ii) causes catastrophic failure of blocked RF. Here, we investigated the influence of RPA availability on chemosensitivity using a panel of human HGSOC cell lines. Our data revealed a striking correlation among these cell lines between cisplatin sensitivity and the inability to efficiently repair DNA via NER, specifically during S phase. Such defects in NER were attributable to RPA exhaustion arising from aberrant activation of DNA replication origins during replication stress. Reduced RPA availability promoted Mre11-dependent degradation of nascent DNA at stalled RF in cell lines exhibiting elevated sensitivity to cisplatin. Strikingly, defective S-phase NER, RF instability, and cisplatin sensitivity could all be rescued by ectopic overexpression of RPA. Taken together, our findings indicate that RPA exhaustion represents a major determinant of cisplatin sensitivity in HGSOC cell lines. Significance: The influence of replication protein A exhaustion on cisplatin sensitivity harbors important implications toward improving therapy of various cancers that initially respond to platinum-based agents but later relapse due to intrinsic or acquired drug resistance. Cancer Res; 78(19); 5561–73. ©2018 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Upon severe UV-induced replication stress, excessive sequestration of RPA on ssDNA located at persistently stalled replication forks, or at aberrantly activated origins of replication, was shown by our group and others to limit the availability of this complex to act in NER during S phase (10, 11, 14).”
From A genome-wide screen reveals that Dyrk1A kinase promotes nucleotide excision repair by preventing aberrant overexpression of cyclin D1 and p21 (2023) · cites this paper as [11]
In the citing paper
“We previously demonstrated that defective responses to DNA replication stress, for example, in cells depleted for ataxia telangiectasia and rad 3-related kinase (ATR) or translesion DNA polymerase eta (pol eta), cause striking GG-NER defects during S phase, whereas repair in G1 or G2/M is not significantly impacted (GG-NER during S phase is hereafter denoted S phase NER) (8, 9, 10, 11).”
From A genome-wide screen reveals that Dyrk1A kinase promotes nucleotide excision repair by preventing aberrant overexpression of cyclin D1 and p21 (2023) · cites this paper as [11]
In the citing paper
“we and others previously demonstrated that such defects can be caused by abnormal replicative stress responses (e.g., in ATR- and pol eta-deficient cells), leading to excessive sequestration of heterotrimeric RPA in trans at persistently stalled replication forks or aberrantly activated origins of replication, which in turn prevents the essential action of this complex in NER (10, 11, 14).”
From A genome-wide screen reveals that Dyrk1A kinase promotes nucleotide excision repair by preventing aberrant overexpression of cyclin D1 and p21 (2023) · cites this paper as [11]
In the citing paper
“(ii) strongly associated with chemosensitivity in ovarian cancer cells (11)”
From A genome-wide screen reveals that Dyrk1A kinase promotes nucleotide excision repair by preventing aberrant overexpression of cyclin D1 and p21 (2023) · cites this paper as [11]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 50 · Cited by 58
Metadata
- Authors
- Bélanger, F., Fortier, E., Dubé, M., Lemay, J.-F., Buisson, R., Masson, J.-Y., Elsherbiny, A., Costantino, S., Carmona, E., Mes-Masson, A.-M., Wurtele, H., & Drobetsky, E.
- Affiliations
- Hôpital Maisonneuve-Rosemont (CA)
- 1Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Canada.
- Université Laval (CA)
- 5Centre de Recherche du Centre Hospitalier de l'Université de Montréal, and Institut du Cancer de Montréal, Montréal, Canada.
- 2Programme de Biologie Moléculaire, Université de Montréal, Montréal, Canada.
- ORCID
- Venue
- Cancer Research
- Published
- 2018-10-01
- Volume
- 78
- Issue
- 19
- Pages
- 5561-5573
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2885846020
- Semantic Scholar
- 6510bae31365da613520dd9cc0f7d23209262646
- Cited by
- 58
- References
- 50
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 7 · 2023: 8 · 2022: 6 · 2021: 9 · 2020: 14 · 2019: 6 · 2018: 2
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Gouvernement du Canada | Canadian Institutes of Health Research (CIHR) (364096)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- replication protein A, cisplatin resistance, high-grade serous ovarian cancer, replication stress, single-stranded DNA, nucleotide excision repair, MRE11, origin of replication, platinum-based chemotherapy, drug resistance
- MeSH terms
- Cisplatin, DNA Damage, DNA Repair, DNA Replication, DNA, Single-Stranded, Female, Humans, Ovarian Neoplasms, Drug Resistance, Neoplasm, RNA, Small Interfering, Cell Line, Tumor, Replication Protein A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Replication Protein A Availability during DNA Replication Stress Is a Major Determinant of Cisplatin Resistance in Ovarian Cancer Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-18-0618
- The paper
- Bélanger, F., Fortier, E., Dubé, M., Lemay, J.-F., Buisson, R., Masson, J.-Y., Elsherbiny, A., Costantino, S., Carmona, E., Mes-Masson, A.-M., Wurtele, H., & Drobetsky, E. (2018). Replication Protein A Availability during DNA Replication Stress Is a Major Determinant of Cisplatin Resistance in Ovarian Cancer Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-18-0618
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.